Additionally, a study of prostate cancer cells with inhibited BRG1 found that several of BRG1’s target genes were decreased, including protein KLK2 [19], a known apoptosis inhibitor in prostate cancer [49]. This evidence concerns the gene KLK2 and prostate carcinoma.